

## **Largest South American Blood Center Initiates Use of ITL's SSK**

ITL BioMedical, a division of ITL Health Group (ASX: ITD), that sets industry standards for the innovative design and production of biological sampling systems, is pleased to announce that the Pró-Sangue blood center in Brazil has begun using ITL's SampLok Sampling Kit (SSK).

Pró-Sangue is the largest blood center in South America. It is a public institution linked to the Health State Secretary and to the Faculty of Medicine of the University of São Paulo.

ITL BioMedical is a growing provider of specialty ancillary products for the blood culture testing market, estimated to be worth US\$3.3b in 2016 and growing to US\$4.8b by 2021<sup>(1)</sup>. SSK is a highly innovative product that is utilized in the blood banking market to transfer platelet samples during bacterial detection testing. It offers state of the art product design that facilitates product sampling for laboratory testing process efficiencies, safety in reducing potential for needlestick injuries and reduced biohazard waste, among other benefits.

Bill Mobbs, Executive Chairman of ITL Health Group, commented. "The expansion of SSK to Brazil's largest pre-eminent blood center represents exciting potential for the product in the South American market".

"The Pró-Sangue implementation is in line with ITL's strategy of expanding sales of SSK around the globe. This strategy has proven to be successful and continues to drive strong growth."

Bill Mobbs  
Executive Chairman

(1) [www.marketsandmarkets.com/PressReleases/blood-culture-test.as](http://www.marketsandmarkets.com/PressReleases/blood-culture-test.as)

**About ITL BioMedical – [www.ITLBioMedical.com](http://www.ITLBioMedical.com)**

ITL BioMedical is a division of ITL that sets industry standards for the innovative design and production of biological sampling systems for human and animal use. The Division's patented medical devices focus on safety and process efficiency for end-users and their blood donors and patients in healthcare markets worldwide.

### **ITL Health Group**

ITL is an innovative global medical technology company made up of four divisions; ITL BioMedical, ITL Healthcare, ITL Clinical & MyHealthTest.

ITL creates & manufactures leading edge medical devices for the clinical, blood banking, & laboratory markets & is a growing provider of specialist ancillary products for the blood culture testing market.

ITL holds an IP portfolio of 48 patents & sells into 55 countries.

MyHealthTest creates and markets highly innovative direct to consumer pathology testing for major chronic diseases.



Ranked 16<sup>th</sup> most Innovative Company by the  
AFR Innovative Companies Awards

### **Australian Securities Exchange**

Code: ITD

### **Ordinary Shares**

95,928,314

### **Board of Directors**

Bill Mobbs	Executive Chairman
Mark Peatey	Non-executive Director
Andrew Turnbull	Non-executive Director

Trevor Doolan	Chief Financial Officer & Company Secretary
---------------	--

### **ITL Contact**

Trevor Doolan	Company Secretary
Phone:	+61 3 8773 3050
Email:	<a href="mailto:info@itl-limited.com">info@itl-limited.com</a>
Address	Unit 1, 63 Wells Road Chelsea Heights, Victoria, 3196

[www.itlhealthgroup.com](http://www.itlhealthgroup.com)

### **Media**

Walbrook IR	Ben Knowles
Phone:	+61 426 277 760
Email:	<a href="mailto:ben.knowles@walbrookir.co.au">ben.knowles@walbrookir.co.au</a>

**About Pró-Sangue - [www.prosangue.sp.gov.br](http://www.prosangue.sp.gov.br)**

Created in 1984, the Pró-Sangue Foundation is the largest blood bank in Latin America and the collected blood plasma quantity is equivalent to approximately 32% of the total consumed at São Paulo Metropolitan Zone. The Pró-Sangue Foundation is a public institution, linked to the Health State Secretary and to the Hospital das Clínicas (Clínicas Hospital) of University of São Paulo's Medicine College, with which it maintains close academic and technical-scientific co-operation.

During its 27 years of existence, Pró-Sangue Foundation has provided significant advances to the development of the hematological and hemotherapeutic activities in the country.